Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Operating activities    
Net loss $ (14,250) $ (12,046)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:    
Depreciation and amortization 1,137 1,162
Accretion of discount on marketable securities (600) 0
Stock-based compensation 2,286 264
Reduction of the liability attributable to a research, development and commercialization agreement (127) 0
Accretion of debt discount 42 38
Revaluation of SutroVax option liability 14 0
Other 17 35
Changes in operating assets and liabilities:    
Accounts receivable (849) (2,531)
Prepaid expenses and other assets 336 (130)
Accounts payable 476 (189)
Accrued compensation (3,715) 980
Other liabilities 397 44
Deferred rent (7) 21
Deferred revenue (5,302) (2,658)
Net cash used in operating activities (20,145) (15,010)
Investing activities    
Purchases of marketable securities (119,053) 0
Maturities of marketable securities 37,750 0
Sales of marketable securities 3,500 0
Purchases of property and equipment (276) (364)
Net cash used in investing activities (78,079) (364)
Financing activities    
Payment of deferred offering costs 0 (52)
Payment of debt (500) 0
Proceeds from exercise of common stock options 42 38
Net cash used in by financing activities (458) (14)
Net decrease in cash, cash equivalents and restricted cash (98,682) (15,388)
Cash, cash equivalents and restricted cash at beginning of period 125,313 22,035
Cash, cash equivalents and restricted cash at end of period 26,631 6,647
Supplemental disclosure of cash flow information:    
Cash paid for interest 330 300
Supplemental disclosure of non-cash investing and financing information:    
Vesting of early exercised shares 0 14
Purchase of property and equipment included in accounts payable 63 5
Deferred initial public offering costs included in accounts payable 0 53
Embedded interest associated with program fees $ 860 $ 0